Castle Biosciences (NASDAQ:CSTL) Given Sell (D-) Rating at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Castle Biosciences (NASDAQ:CSTL) in a report issued on Thursday morning,Weiss Ratings reports.

CSTL has been the topic of several other reports. Zacks Research upgraded Castle Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $37.00 price objective on shares of Castle Biosciences in a report on Tuesday, September 9th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.57.

Castle Biosciences Trading Up 2.0%

Shares of NASDAQ CSTL opened at $24.21 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.69 and a current ratio of 6.85. The business’s 50 day moving average price is $23.04 and its 200-day moving average price is $20.04. Castle Biosciences has a fifty-two week low of $14.59 and a fifty-two week high of $35.84. The company has a market cap of $702.33 million, a price-to-earnings ratio of -69.17 and a beta of 1.13.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Monday, August 4th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.66. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%.The firm had revenue of $86.18 million for the quarter, compared to the consensus estimate of $71.53 million. Castle Biosciences has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Castle Biosciences will post 0.44 earnings per share for the current year.

Insider Buying and Selling at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 1,339 shares of the company’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $22.44, for a total transaction of $30,047.16. Following the transaction, the insider owned 62,988 shares in the company, valued at approximately $1,413,450.72. This represents a 2.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after purchasing an additional 655 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Castle Biosciences by 1.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock worth $1,439,000 after acquiring an additional 707 shares during the period. Diversify Wealth Management LLC lifted its position in Castle Biosciences by 5.8% during the 1st quarter. Diversify Wealth Management LLC now owns 13,102 shares of the company’s stock worth $260,000 after acquiring an additional 717 shares during the period. Inspire Investing LLC lifted its position in Castle Biosciences by 4.0% during the 3rd quarter. Inspire Investing LLC now owns 19,887 shares of the company’s stock worth $453,000 after acquiring an additional 770 shares during the period. Finally, CWM LLC lifted its position in Castle Biosciences by 80.6% during the 3rd quarter. CWM LLC now owns 1,911 shares of the company’s stock worth $44,000 after acquiring an additional 853 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.